Letermovir for R+ Study
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Wisconsin, Madison
About this trial
The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been exposed the CMV.
Participants will take letermovir for 84 days.
Eligibility criteria
Qualifiers
Adults who are at moderate risk for CMV after transplant (CMV IGG+, including D+/R+ or D-/R+)
Adults who received a kidney transplant, liver transplant, or any combination thereof
Disqualifiers
Known contraindication to letermovir or its excipients
Current participation in another CMV related study
Unwilling or unable to participate in the study protocol
Trial design
Treatments tested in this trial
- Letermovir
Treatment groups
146 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Wisconsin, Madison
Lead sponsor
Merck Sharp & Dohme LLC
Collaborator
Source ClinicalTrials.gov